Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Acute Myocardial Infarction

In brief

VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.

Key facts

Study ID
NCT01950299
Run by
Virginia Commonwealth University
People needed
99
Starts
2014-07-01
Expected to finish
2018-12-23
Last updated by the study team
2019-12-18

Who can join

Age: 21 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.